All In Biotech

Drug Trial Radar · NCT06173518

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

A Single-Arm, Open-Label, Multicenter, Phase 1b/2 Study Evaluating the Safety and Efficacy of AUTO1 (Obecabtagene Autoleucel [Obe-cel]) in Pediatric Patients With CD19-positive Relapsed/Refractory (R/R) B Cell Acute Lymphoblastic Leukemia (B ALL) or R/R Aggressive Mature B Cell Non-Hodgkin Lymphoma (B NHL).

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Nov 16, 2023

Primary completion

Nov 2027

Study completion Nov 2027

Sponsor

Lead sponsor
Autolus LimitedIndustry
Sponsor type
Industry
First posted
Dec 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non-Hodgkin lymphoma (B NHL).

Conditions

  • Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
  • Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Interventions

  • AUTO1Biological

    Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with anti-CD19 chimeric antigen receptor (CAR) T cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: Up to 24 months
  2. Incidence and duration of severe hypogammaglobulinemiaTime frame: Up to 24 months
  3. Proportion of pediatric participants with r/r B ALL at screening who achieve complete remission (CR) within 3 months of obe-cel infusion per Independent Response Review Committee (IRRC) assessmentTime frame: 3 months

Locations

15 sites in 3 countries. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles

    Los Angeles, California · Recruiting

  • Lucile Packard Children's Hospital, Stanford University

    Palo Alto, California · Recruiting

  • Children's Hospital Colorado

    Aurora, Colorado · Recruiting

  • Arthur M Blank Hospital

    Atlanta, Georgia · Recruiting

  • Lurie Children's Hospital

    Chicago, Illinois · Recruiting

  • Cincinnati Children's Hospital

    Cincinnati, Ohio · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Methodist Children's Hospital

    San Antonio, Texas · Recruiting

  • Primary Children's Hospital

    Salt Lake City, Utah · Recruiting

  • Seattle Children's Hospital

    Seattle, Washington · Recruiting

  • Hospital Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital Nino Jesus

    Madrid, Spain · Recruiting

  • Great Ormond Street Hospital for Children NHS Foundation Trust

    London, United Kingdom · Recruiting

  • Royal Manchester Children's Hospital

    Manchester, United Kingdom · Recruiting

  • Great North Children's Hospital

    Newcastle upon Tyne, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.